Provided by Tiger Trade Technology Pte. Ltd.

TherapeuticsMD

2.01
0.0000
Volume:4K
Turnover:7.65K
Market Cap:23.26M
PE:-107.21
High:2.04
Open:2.00
Low:1.99
Close:2.01
52wk High:2.95
52wk Low:1.03
Shares:11.57M
Float Shares:9.49M
Volume Ratio:0.79
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0187
EPS(LYR):-0.0527
ROE:-1.08%
ROA:-2.88%
PB:0.86
PE(LYR):-38.11

Loading ...

TherapeuticsMD Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Oct 06

TherapeuticsMD Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

TherapeuticsMD Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

TherapeuticsMD Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 23

TherapeuticsMD Inc. Stock Slips 4.1%, Underperforms Market

Dow Jones
·
Sep 22

TherapeuticsMD Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 12

TherapeuticsMD Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

TherapeuticsMD Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 05

TherapeuticsMD Inc. Stock Climbs 4.1%, Outperforms Market

Dow Jones
·
Sep 03

TherapeuticsMD Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Sep 01

TherapeuticsMD Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Aug 28

TherapeuticsMD Inc. Stock Rallies 10.1%, Outperforms Market

Dow Jones
·
Aug 26

TherapeuticsMD Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 21

TherapeuticsMD Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Aug 18

Karyopharm Q2 Revenue Falls as License Revenue Drops; Expects Funds to Last into September

Reuters
·
Aug 13

Indaptus Q2 Net Loss Narrows as Costs Fall

Reuters
·
Aug 13

Canada's Cipher Pharma Q2 Revenue Falls on Lower Natroba Sales Amid Reduced Medicaid Coverage

Reuters
·
Aug 12

TherapeuticsMD Q2 Results and Strategic Alternatives Review

TIPRANKS
·
Aug 12

TherapeuticsMD Q2 EPS $0.01 Down From $0.05 YoY, Sales $869.000K Down From $952.000K YoY

Benzinga Earnings
·
Aug 12

TherapeuticsMD Q2 License Revenue Falls; Continues to Evaluate Strategic Alternatives

Reuters
·
Aug 12